US825A
(en)
|
|
1838-07-09 |
|
Bail way cooking-stove |
US5569A
(en)
|
|
1848-05-16 |
|
Corn-sheller |
US4044126A
(en)
|
1972-04-20 |
1977-08-23 |
Allen & Hanburys Limited |
Steroidal aerosol compositions and process for the preparation thereof
|
GB1429184A
(en)
|
1972-04-20 |
1976-03-24 |
Allen & Hanburys Ltd |
Physically anti-inflammatory steroids for use in aerosols
|
US4444887A
(en)
|
1979-12-10 |
1984-04-24 |
Sloan-Kettering Institute |
Process for making human antibody producing B-lymphocytes
|
US4716111A
(en)
|
1982-08-11 |
1987-12-29 |
Trustees Of Boston University |
Process for producing human antibodies
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
DE3668186D1
(en)
|
1985-04-01 |
1990-02-15 |
Celltech Ltd |
TRANSFORMED MYELOMA CELL LINE AND METHOD USING THE SAME FOR EXPRESSING A GENE ENCODING AN EUKARYONTIC POLYPEPTIDE.
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
EP0768377A1
(en)
|
1988-09-02 |
1997-04-16 |
Protein Engineering Corporation |
Generation and selection of recombinant varied binding proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5585112A
(en)
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
US5780225A
(en)
|
1990-01-12 |
1998-07-14 |
Stratagene |
Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
|
WO1991010737A1
(en)
|
1990-01-11 |
1991-07-25 |
Molecular Affinities Corporation |
Production of antibodies using gene libraries
|
SG48759A1
(en)
|
1990-01-12 |
2002-07-23 |
Abgenix Inc |
Generation of xenogenic antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
IT1246382B
(en)
|
1990-04-17 |
1994-11-18 |
Eurand Int |
METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
KR100272077B1
(en)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
ATE164395T1
(en)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
|
CA2108147C
(en)
|
1991-04-10 |
2009-01-06 |
Angray Kang |
Heterodimeric receptor libraries using phagemids
|
DE69233482T2
(en)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
CA2110799A1
(en)
|
1991-06-14 |
1992-12-23 |
Arnold H. Horwitz |
Microbially-produced antibody fragments and their conjugates
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
US5885793A
(en)
|
1991-12-02 |
1999-03-23 |
Medical Research Council |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
CA2103887C
(en)
|
1991-12-13 |
2005-08-30 |
Gary M. Studnicka |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
US6010715A
(en)
|
1992-04-01 |
2000-01-04 |
Bertek, Inc. |
Transdermal patch incorporating a polymer film incorporated with an active agent
|
US6024975A
(en)
|
1992-04-08 |
2000-02-15 |
Americare International Diagnostics, Inc. |
Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
|
AU4116793A
(en)
|
1992-04-24 |
1993-11-29 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
DE69334305D1
(en)
|
1992-08-21 |
2010-01-28 |
Univ Bruxelles |
Immunoglobulins without light chains
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
EP0672142B1
(en)
|
1992-12-04 |
2001-02-28 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
US6274552B1
(en)
|
1993-03-18 |
2001-08-14 |
Cytimmune Sciences, Inc. |
Composition and method for delivery of biologically-active factors
|
US5985307A
(en)
|
1993-04-14 |
1999-11-16 |
Emory University |
Device and method for non-occlusive localized drug delivery
|
US5523092A
(en)
|
1993-04-14 |
1996-06-04 |
Emory University |
Device for local drug delivery and methods for using the same
|
WO1994025591A1
(en)
|
1993-04-29 |
1994-11-10 |
Unilever N.V. |
PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
US6004534A
(en)
|
1993-07-23 |
1999-12-21 |
Massachusetts Institute Of Technology |
Targeted polymerized liposomes for improved drug delivery
|
AU696293B2
(en)
|
1993-12-08 |
1998-09-03 |
Genzyme Corporation |
Process for generating specific antibodies
|
US5997873A
(en)
|
1994-01-13 |
1999-12-07 |
Mount Sinai School Of Medicine Of The City University Of New York |
Method of preparation of heat shock protein 70-peptide complexes
|
AU1736495A
(en)
|
1994-01-31 |
1995-08-15 |
Trustees Of Boston University |
Polyclonal antibody libraries
|
US6719972B1
(en)
|
1994-06-03 |
2004-04-13 |
Repligen Corporation |
Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
|
US5516637A
(en)
|
1994-06-10 |
1996-05-14 |
Dade International Inc. |
Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
|
US5759542A
(en)
|
1994-08-05 |
1998-06-02 |
New England Deaconess Hospital Corporation |
Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
|
US5660854A
(en)
|
1994-11-28 |
1997-08-26 |
Haynes; Duncan H |
Drug releasing surgical implant or dressing material
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5983134A
(en)
|
1995-04-23 |
1999-11-09 |
Electromagnetic Bracing Systems Inc. |
Electrophoretic cuff apparatus drug delivery system
|
EP1978033A3
(en)
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
AU2466895A
(en)
|
1995-04-28 |
1996-11-18 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6316652B1
(en)
|
1995-06-06 |
2001-11-13 |
Kosta Steliou |
Drug mitochondrial targeting agents
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US6167301A
(en)
|
1995-08-29 |
2000-12-26 |
Flower; Ronald J. |
Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
|
US5935576A
(en)
|
1995-09-13 |
1999-08-10 |
Fordham University |
Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
|
GB9601081D0
(en)
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
US5989830A
(en)
|
1995-10-16 |
1999-11-23 |
Unilever Patent Holdings Bv |
Bifunctional or bivalent antibody fragment analogue
|
US6039975A
(en)
|
1995-10-17 |
2000-03-21 |
Hoffman-La Roche Inc. |
Colon targeted delivery system
|
JP2978435B2
(en)
|
1996-01-24 |
1999-11-15 |
チッソ株式会社 |
Method for producing acryloxypropyl silane
|
JP4046354B2
(en)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
Immunoglobulin-like domain with increased half-life
|
TW345603B
(en)
|
1996-05-29 |
1998-11-21 |
Gmundner Fertigteile Gmbh |
A noise control device for tracks
|
US6027947A
(en)
|
1996-08-20 |
2000-02-22 |
Ramtron International Corporation |
Partially or completely encapsulated top electrode of a ferroelectric capacitor
|
US5985317A
(en)
|
1996-09-06 |
1999-11-16 |
Theratech, Inc. |
Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
|
AU722289B2
(en)
|
1996-10-01 |
2000-07-27 |
Aptalis Pharmatech, Inc. |
Taste-masked microcapsule compositions and methods of manufacture
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
US6131570A
(en)
|
1998-06-30 |
2000-10-17 |
Aradigm Corporation |
Temperature controlling device for aerosol drug delivery
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
KR100942002B1
(en)
|
1996-12-03 |
2010-02-12 |
암젠 프레몬트 인코포레이티드 |
Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
|
US20060034844A1
(en)
|
1996-12-04 |
2006-02-16 |
The Regents Of The University Of California |
Stimulation of T cells against self antigens using CTLA-4 blocking agents
|
US5860957A
(en)
|
1997-02-07 |
1999-01-19 |
Sarcos, Inc. |
Multipathway electronically-controlled drug delivery system
|
US6017540A
(en)
|
1997-02-07 |
2000-01-25 |
Fordham University |
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
AU6703198A
(en)
|
1997-03-21 |
1998-10-20 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
US7227002B1
(en)
|
1997-04-14 |
2007-06-05 |
Micromet Ag |
Human antibodies that bind human 17-A1/EpCAM tumor antigen
|
US6060082A
(en)
|
1997-04-18 |
2000-05-09 |
Massachusetts Institute Of Technology |
Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US5948433A
(en)
|
1997-08-21 |
1999-09-07 |
Bertek, Inc. |
Transdermal patch
|
US6267983B1
(en)
|
1997-10-28 |
2001-07-31 |
Bando Chemical Industries, Ltd. |
Dermatological patch and process for producing thereof
|
US5948646A
(en)
|
1997-12-11 |
1999-09-07 |
Fordham University |
Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
|
CA2323746A1
(en)
|
1998-03-19 |
1999-09-23 |
Heska Corporation |
T cell costimulatory proteins, sequences and uses thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6048736A
(en)
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
PT1137436E
(en)
|
1998-12-03 |
2008-09-15 |
Univ California |
Stimulation of t-cells against self antigens using ctla-4 blocking agents
|
EE05627B1
(en)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
Human monoclonal antibodies to CTLA-4
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
KR100887482B1
(en)
|
1999-01-15 |
2009-03-10 |
제넨테크, 인크. |
Polypeptide Variants with Altered Effector Function
|
US6271359B1
(en)
|
1999-04-14 |
2001-08-07 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
US6256533B1
(en)
|
1999-06-09 |
2001-07-03 |
The Procter & Gamble Company |
Apparatus and method for using an intracutaneous microneedle array
|
JP4896327B2
(en)
|
1999-08-23 |
2012-03-14 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
PD-1, B7-4 receptors and uses thereof
|
EP1212422B1
(en)
*
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
ATE440111T1
(en)
|
1999-11-29 |
2009-09-15 |
Bac Ip B V |
IMMOBILIZED ANTIGEN BINDING MOLECULES FROM A DOMAIN
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
AU2001233027A1
(en)
|
2000-01-27 |
2001-08-07 |
Genetics Institute, Llc |
Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
|
EP1125905A1
(en)
|
2000-02-16 |
2001-08-22 |
Pepscan Systems B.V. |
Segment synthesis
|
US6261595B1
(en)
|
2000-02-29 |
2001-07-17 |
Zars, Inc. |
Transdermal drug patch with attached pocket for controlled heating device
|
EP1274733A1
(en)
|
2000-04-12 |
2003-01-15 |
Genetics Institute, Inc. |
Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor
|
EP1197755A1
(en)
|
2000-10-11 |
2002-04-17 |
Pepscan Systems B.V. |
Identification of protein binding sites
|
KR100857943B1
(en)
|
2000-11-30 |
2008-09-09 |
메다렉스, 인코포레이티드 |
Transgenic Transchromosomal Rodents for Making Human Antibodies
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
WO2002060919A2
(en)
|
2000-12-12 |
2002-08-08 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
CA2438415A1
(en)
|
2001-02-16 |
2002-08-29 |
Pepscan Systems B.V. |
Pixel arrays
|
IL149701A0
(en)
|
2001-05-23 |
2002-11-10 |
Pfizer Prod Inc |
Use of anti-ctla-4 antibodies
|
MXPA05000511A
(en)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Super humanized antibodies.
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
AUPS054702A0
(en)
|
2002-02-14 |
2002-03-07 |
Immunaid Pty Ltd |
Cancer therapy
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20040014194A1
(en)
|
2002-03-27 |
2004-01-22 |
Schering Corporation |
Beta-secretase crystals and methods for preparing and using the same
|
MXPA04010013A
(en)
|
2002-04-12 |
2004-12-13 |
Medarex Inc |
Methods of treatement using ctla-4 antibodies.
|
RU2375077C2
(en)
|
2002-05-02 |
2009-12-10 |
Юниверсити Оф Коннектикут Хелт Сентер |
Application of heat-shock proteins for improving effectiveness of antibody therapies
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
ATE481985T1
(en)
|
2002-07-03 |
2010-10-15 |
Ono Pharmaceutical Co |
IMMUNOPOTENTATING COMPOSITIONS
|
EP1549678A4
(en)
|
2002-09-30 |
2006-01-18 |
Pfizer Prod Inc |
Hybridomas producing high levels of human sequence antibody
|
ES2367430T3
(en)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
ANTIBODIES AGAINST PD-1 AND ITS USES.
|
US9068234B2
(en)
|
2003-01-21 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating gene expression
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
JP2007528723A
(en)
|
2003-08-22 |
2007-10-18 |
メディミューン,インコーポレーテッド |
Antibody humanization
|
WO2005092380A2
(en)
|
2004-03-26 |
2005-10-06 |
Pfizer Products Inc |
Uses of anti-ctla-4 antibodies
|
US7494779B2
(en)
|
2004-06-14 |
2009-02-24 |
Li-Te Chin |
Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
|
US20060057626A1
(en)
|
2004-09-03 |
2006-03-16 |
Nichol Geoffrey M |
Assessment of CTLA-4 polymorphisms in CTLA-4 blockade therapy
|
EP1793858A4
(en)
|
2004-09-08 |
2008-12-10 |
Univ Ohio State Res Found |
Human monoclonal anti-ctla4 antibodies in cancer treatment
|
DE102004063494A1
(en)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
antibody
|
BRPI0608815B1
(en)
|
2005-03-08 |
2021-10-13 |
Pfizer Products Inc |
ANTI-CTLA-4 ANTIBODY COMPOSITIONS
|
US20060240006A1
(en)
|
2005-04-20 |
2006-10-26 |
Chishih Chu |
Novel antibody structures derived from human germline sequences
|
EP1896582A4
(en)
|
2005-05-09 |
2009-04-08 |
Ono Pharmaceutical Co |
Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
JP2006327937A
(en)
|
2005-05-23 |
2006-12-07 |
Ritsutoku Kin |
Human antibody structure equipped with human germ cell line gene structure and derived fragment of the same
|
KR101600225B1
(en)
|
2005-06-08 |
2016-03-04 |
다나-파버 캔서 인스티튜트 인크. |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
|
CA2612241C
(en)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
US20070243184A1
(en)
|
2005-11-08 |
2007-10-18 |
Steven Fischkoff |
Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
|
AU2006321593B2
(en)
|
2005-12-07 |
2012-10-04 |
E. R. Squibb & Sons, L.L.C. |
CTLA-4 antibody dosage escalation regimens
|
PT1962886E
(en)
|
2005-12-20 |
2014-01-07 |
Bristol Myers Squibb Co |
Stable protein formulations
|
JP6092497B2
(en)
|
2006-03-30 |
2017-03-08 |
ユニバーシティー オブ カリフォルニア |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
US7919079B2
(en)
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
EP2007423A2
(en)
|
2006-04-05 |
2008-12-31 |
Pfizer Products Incorporated |
Ctla4 antibody combination therapy
|
CN101074264B
(en)
|
2006-05-17 |
2011-08-17 |
上海抗体药物国家工程研究中心有限公司 |
Recombinant anti-CTLA4 monoclonal antibody, its production and use
|
EP2102241A2
(en)
|
2006-12-15 |
2009-09-23 |
Ablynx N.V. |
Amino acid sequences that modulate the interaction between cells of the immune system
|
NZ596237A
(en)
|
2006-12-27 |
2012-07-27 |
Dana Farber Cancer Inst Inc |
Compositions and methods for the treatment of infections and tumors
|
US20100055111A1
(en)
|
2007-02-14 |
2010-03-04 |
Med. College Of Georgia Research Institute, Inc. |
Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
PL2170959T3
(en)
|
2007-06-18 |
2014-03-31 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
CA2693677C
(en)
|
2007-07-12 |
2018-02-13 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
PE20120259A1
(en)
*
|
2007-08-09 |
2012-04-04 |
Boehringer Ingelheim Int |
ANTI-CD37 ANTIBODIES
|
EP3492488A1
(en)
|
2007-08-22 |
2019-06-05 |
The Regents of The University of California |
Activatable binding polypeptides and methods of identification and use thereof
|
US7968300B2
(en)
|
2007-11-21 |
2011-06-28 |
Li-Te Chin |
Method of isolating regulatory T cells from human samples
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
CN101909693A
(en)
|
2008-01-08 |
2010-12-08 |
百时美施贵宝公司 |
Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
|
US8263073B2
(en)
|
2008-02-04 |
2012-09-11 |
Medarex, Inc. |
Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
|
RU2531758C2
(en)
|
2008-02-11 |
2014-10-27 |
Куретек Лтд. |
Monoclonal antibodies for tumour treatment
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Pd-1 binding proteins
|
PE20110308A1
(en)
|
2008-07-08 |
2011-06-10 |
Incyte Corp |
1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLAMINE 2,3-DIOXYGENASE
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
AR072999A1
(en)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
|
PL2350129T3
(en)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc |
Compositions of pd-1 antagonists and methods of use
|
WO2010029435A1
(en)
|
2008-09-12 |
2010-03-18 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
CA2998281C
(en)
|
2008-09-26 |
2022-08-16 |
Dana-Farber Cancer Institute, Inc. |
Human anti-pd-1 antobodies and uses therefor
|
HRP20240240T1
(en)
|
2008-12-09 |
2024-04-26 |
F. Hoffmann - La Roche Ag |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
JP5851842B2
(en)
|
2009-01-12 |
2016-02-03 |
サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. |
Modified antibody composition and methods of making and using the same
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
CN103833855A
(en)
|
2009-06-26 |
2014-06-04 |
瑞泽恩制药公司 |
Readily isolated bispecific antibodies with native immunoglobulin format
|
AU2010282340B2
(en)
|
2009-08-13 |
2016-12-22 |
The Johns Hopkins University |
Methods of modulating immune function
|
AU2010308030B2
(en)
|
2009-10-12 |
2014-05-29 |
Pfizer Inc. |
Cancer treatment
|
GB0920258D0
(en)
|
2009-11-19 |
2010-01-06 |
Alligator Bioscience Ab |
New medical agents and use thereof
|
LT3279215T
(en)
|
2009-11-24 |
2020-04-10 |
Medimmune Limited |
Targeted binding agents against b7-h1
|
CN102134276A
(en)
|
2010-01-22 |
2011-07-27 |
上海抗体药物国家工程研究中心有限公司 |
Chimeric antibody resisting CTLA-4 (Cytotoxic T Lymphocyte Antigen)
|
WO2011100841A1
(en)
|
2010-02-16 |
2011-08-25 |
Valorisation-Recherche, Limited Partnership |
Pd-1 modulation and uses thereof for modulating hiv replication
|
CN102892786B
(en)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1 antibody
|
JP2013523098A
(en)
|
2010-03-29 |
2013-06-17 |
ザイムワークス,インコーポレイテッド |
Antibody with enhanced or suppressed effector function
|
DE102011002045B4
(en)
|
2010-08-13 |
2014-09-11 |
Johnson Controls Gmbh |
Insert for upholstery recess and vehicle seat
|
GB201103955D0
(en)
*
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
RU2625034C2
(en)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Antibodies and other molecules binding b7-h1 and pd-1
|
US9328170B2
(en)
|
2011-05-25 |
2016-05-03 |
Merck Sharp & Dohme Corp. |
Method for preparing Fc containing polypeptides having improved properties
|
CA2840170A1
(en)
|
2011-06-21 |
2012-12-27 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
WO2013014668A1
(en)
|
2011-07-24 |
2013-01-31 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
ES2893855T3
(en)
|
2011-08-11 |
2022-02-10 |
Ono Pharmaceutical Co |
Therapeutic agent for autoimmune diseases comprising PD-1 agonist
|
US8920075B2
(en)
|
2011-09-01 |
2014-12-30 |
Halo Maritime Defense Systems, Inc. |
Marine barrier and gate
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
US9624298B2
(en)
|
2011-11-28 |
2017-04-18 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
US20150037346A1
(en)
|
2012-02-23 |
2015-02-05 |
Sloan-Kettering Institute For Cancer Research |
Prediction of Responsiveness to Treatment with Immunomodulatory Therapeutics and Method of Monitoring Abscopal Effects During Such Treatment
|
US20150079100A1
(en)
|
2012-03-23 |
2015-03-19 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla-4 antibodies
|
JP6434905B2
(en)
|
2012-05-04 |
2018-12-05 |
ファイザー・インク |
Immunotherapy regimens based on prostate-related antigens and vaccines
|
US9863935B2
(en)
|
2012-05-08 |
2018-01-09 |
H. Lee Moffitt Cancer And Research Institute, Inc. |
Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy
|
BR122022015975B1
(en)
|
2012-05-15 |
2024-01-02 |
Bristol-Myers Squibb Company |
MONOCLONAL ANTIBODIES, KIT FOR THE TREATMENT OF AN INDIVIDUAL AFFLICTED WITH A CANCER, PROCESS FOR MEASURING MEMBRANOUS PD-L1 ON ISOLATED TUMOR CELLS AND USE OF THE ANTIBODY OR A PORTION THAT BIDS TO THE ANTIGEN THEREOF
|
EP3553086A1
(en)
|
2012-05-31 |
2019-10-16 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind pd-l1
|
US9856314B2
(en)
|
2012-06-22 |
2018-01-02 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and methods of using the same
|
SG11201408554QA
(en)
|
2012-06-22 |
2015-02-27 |
Cytomx Therapeutics Inc |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
AR091649A1
(en)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
|
US11180572B2
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Dimeric protein with triple mutations
|
WO2014022758A1
(en)
|
2012-08-03 |
2014-02-06 |
Dana-Farber Cancer Institute, Inc. |
Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
|
KR101947702B1
(en)
|
2012-10-04 |
2019-02-14 |
다나-파버 캔서 인스티튜트 인크. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
WO2014066532A1
(en)
|
2012-10-23 |
2014-05-01 |
Bristol-Myers Squibb Company |
Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
|
EP2911669B1
(en)
|
2012-10-26 |
2024-04-10 |
The University of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
HUE043903T2
(en)
|
2012-12-03 |
2019-09-30 |
Bristol Myers Squibb Co |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
AR093984A1
(en)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
|
JP6605957B2
(en)
|
2013-01-04 |
2019-11-13 |
シトムクス セラピューティクス,インコーポレイティド |
Compositions and methods for detecting protease activity in biological systems
|
MX368665B
(en)
|
2013-03-15 |
2019-10-10 |
Abbvie Biotherapeutics Inc |
Fc variants.
|
EP3712177A1
(en)
|
2013-03-15 |
2020-09-23 |
GlaxoSmithKline Intellectual Property Development Limited |
Anti-lag-3 binding proteins
|
WO2014179491A2
(en)
|
2013-04-30 |
2014-11-06 |
La Jolla Institute For Allergy And Immunology |
MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-η
|
WO2014179664A2
(en)
|
2013-05-02 |
2014-11-06 |
Anaptysbio, Inc. |
Antibodies directed against programmed death-1 (pd-1)
|
EP3004169B1
(en)
|
2013-05-31 |
2023-03-22 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
US20160145355A1
(en)
|
2013-06-24 |
2016-05-26 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
CN104250302B
(en)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
The anti-antibody of PD 1 and its application
|
US9873740B2
(en)
|
2013-07-16 |
2018-01-23 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
BR112016001420A2
(en)
|
2013-08-02 |
2018-01-23 |
Aduro Biotech Holdings Europe B V |
cd27 agonist combination and immune point inhibition for immune stimulation
|
EP3036255A4
(en)
|
2013-08-22 |
2017-03-22 |
The Council Of The Queensland Institute Of Medical Research |
Immunoreceptor modulation for treating cancer and viral infections
|
WO2015035112A1
(en)
|
2013-09-05 |
2015-03-12 |
The Johns Hopkins University |
Cancer therapy via a combination of epigenetic modulation and immune modulation
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
CN107011441B
(en)
|
2013-09-13 |
2020-12-01 |
百济神州(广州)生物科技有限公司 |
anti-PD 1 antibodies and their use as therapeutic and diagnostic agents
|
HUE062317T2
(en)
|
2013-09-20 |
2023-10-28 |
Bristol Myers Squibb Co |
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
KR102338453B1
(en)
|
2013-10-18 |
2021-12-13 |
리제너론 파아마슈티컬스, 인크. |
Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
|
EP3060581A4
(en)
|
2013-10-25 |
2017-06-07 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
CN104558177B
(en)
|
2013-10-25 |
2020-02-18 |
苏州思坦维生物技术股份有限公司 |
Monoclonal antibody for antagonizing and inhibiting programmed death receptor PD-1and ligand combination thereof, and coding sequence and application thereof
|
IL292510A
(en)
|
2013-11-05 |
2022-06-01 |
Cognate Bioservices Inc |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
ME03527B
(en)
|
2013-12-12 |
2020-04-20 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
EP4079321A1
(en)
|
2014-01-15 |
2022-10-26 |
Kadmon Corporation, LLC |
Immunomodulatory agents
|
TWI680138B
(en)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
Human antibodies to pd-l1
|
WO2015116539A1
(en)
|
2014-01-28 |
2015-08-06 |
Bristol-Myers Squibb Company |
Anti-lag-3 antibodies to treat hematological malignancies
|
CN106103488B
(en)
|
2014-02-10 |
2021-07-30 |
默克专利有限公司 |
Targeted TGF-beta inhibition
|
US20170088626A1
(en)
|
2014-03-05 |
2017-03-30 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
ES2770684T3
(en)
|
2014-03-14 |
2020-07-02 |
Novartis Ag |
LAG-3 Antibody Molecules and Uses thereof
|
US20150283237A1
(en)
|
2014-04-02 |
2015-10-08 |
Mitchell S. Felder |
Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer
|
CN115590953A
(en)
|
2014-05-15 |
2023-01-13 |
百时美施贵宝公司(Us) |
Treatment of lung cancer using a combination of an anti-PD-1 antibody and another anti-cancer agent
|
CA2947932C
(en)
|
2014-05-29 |
2021-03-30 |
Spring Bioscience Corporation |
Pd-l1 antibodies and uses thereof
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
TWI693232B
(en)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
|
EP3160505A4
(en)
|
2014-07-03 |
2018-01-24 |
BeiGene, Ltd. |
Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
|
CA2954841A1
(en)
|
2014-07-16 |
2016-01-21 |
Transgene Sa |
Oncolytic virus for expression of immune checkpoint modulators
|
CN105330740B
(en)
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
Anti- PD-1 antibody and its application
|
CN105296433B
(en)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
A kind of CTLA4 antibody, its medical composition and its use
|
US9982053B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
JO3663B1
(en)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
Anti-lag3 antibodies and antigen-binding fragments
|
WO2016030455A1
(en)
|
2014-08-28 |
2016-03-03 |
Medimmune Limited |
Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
|
RU2710354C2
(en)
|
2014-08-29 |
2019-12-25 |
Ф.Хоффманн-Ля Рош Аг |
Combined therapy based on tumour-targeted immunocytokines containing variant il-2, and antibodies to human pd-l1
|
KR20170060042A
(en)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Combination therapies of alk inhibitors
|
JP2017535528A
(en)
|
2014-10-03 |
2017-11-30 |
ノバルティス アーゲー |
Combination therapy
|
MX2017004810A
(en)
|
2014-10-14 |
2017-10-16 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof.
|
TW201625270A
(en)
|
2014-11-11 |
2016-07-16 |
梅迪繆思有限公司 |
Therapeutic combinations and methods for treating neoplasia
|
WO2016077553A1
(en)
|
2014-11-13 |
2016-05-19 |
The Johns Hopkins University |
Checkpoint blockade and microsatellite instability
|
WO2016100561A2
(en)
|
2014-12-16 |
2016-06-23 |
Bristol-Myers Squibb Company |
Use of immune checkpoint inhibitors in central nervous systems neoplasms
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
US20180021378A1
(en)
|
2014-12-31 |
2018-01-25 |
Anthrogenesis Corporation |
Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
|
JP6917902B2
(en)
|
2015-02-13 |
2021-08-11 |
ソレント・セラピューティクス・インコーポレイテッド |
Antibody drug that binds to CTLA4
|
US10196445B1
(en)
|
2015-03-17 |
2019-02-05 |
Bristol-Myers Squibb Company |
Ipilimumab variant with enhanced ADCC
|
WO2016149387A1
(en)
|
2015-03-18 |
2016-09-22 |
The Johns Hopkins University |
Androgen deprivation with immune checkpoint blockade delays the development of castration resistant prostate cancer
|
US20180094058A1
(en)
*
|
2015-04-17 |
2018-04-05 |
Bioxcel Corporation |
Compositions and methods for preventing tumor growth and treating cancer by targeting lectin galactoside-binding soluble 3 binding protein
|
WO2016179576A1
(en)
*
|
2015-05-07 |
2016-11-10 |
Bioxcel Corporation |
Novel immunomodulatory therapeutic strategies targeting tumors in cancer
|
WO2016183469A1
(en)
|
2015-05-13 |
2016-11-17 |
Robert Kirken |
Anti-ctla-4 blockade
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
AU2016271591A1
(en)
*
|
2015-05-29 |
2017-12-21 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
US10995140B2
(en)
|
2015-06-05 |
2021-05-04 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
|
US10544224B2
(en)
|
2015-07-14 |
2020-01-28 |
Bristol-Myers Squibb Company |
Method of treating cancer using immune checkpoint inhibitor
|
US20180222990A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
EP3331919A1
(en)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
BR112018003186A2
(en)
|
2015-09-01 |
2018-09-25 |
Agenus Inc. |
anti-pd-1 antibodies and their methods of use
|
WO2017062615A2
(en)
|
2015-10-08 |
2017-04-13 |
Macrogenics, Inc. |
Combination therapy for the treatment of cancer
|
WO2017079303A1
(en)
|
2015-11-02 |
2017-05-11 |
The Cleveland Clinic Foundation |
Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
|
WO2017106372A1
(en)
|
2015-12-15 |
2017-06-22 |
Oncoimmune, Inc. |
Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
|
TWI808934B
(en)
|
2015-12-31 |
2023-07-21 |
美商伯克利之光生命科技公司 |
Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide
|
WO2017120612A1
(en)
|
2016-01-10 |
2017-07-13 |
Modernatx, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
ES2924775T3
(en)
|
2016-01-28 |
2022-10-10 |
Inst Nat Sante Rech Med |
Methods and pharmaceutical composition for the treatment of cancer
|
US20170233476A1
(en)
|
2016-02-12 |
2017-08-17 |
Sorrento Therapeutics, Inc. |
Antibody Therapeutics That Bind CTLA4
|
US10358496B2
(en)
|
2016-03-01 |
2019-07-23 |
Ralf Kleef |
Low dose immune checkpoint blockade in metastatic cancer
|
WO2017149150A1
(en)
|
2016-03-04 |
2017-09-08 |
Io Biotech Aps |
Combination therapy against cancer
|
JP7208492B2
(en)
|
2016-03-10 |
2023-01-19 |
シージー オンコロジー, インコーポレイテッド |
Methods of treating solid tumors or lymphoid tumors with combination therapy
|
WO2017160717A2
(en)
|
2016-03-15 |
2017-09-21 |
Memorial Sloan Kettering Cancer Center |
Method of treating diseases using kinase modulators
|
SG10201603721TA
(en)
|
2016-05-10 |
2017-12-28 |
Agency Science Tech & Res |
Anti-CTLA-4 Antibodies
|
CN107400166A
(en)
|
2016-05-19 |
2017-11-28 |
苏州康宁杰瑞生物科技有限公司 |
for CTLA4 single domain antibody and its derived protein
|
IL292302B2
(en)
|
2016-05-20 |
2023-10-01 |
Biohaven Pharm Holding Co Ltd |
Use of glutamate modulating agents with immunotherapies to treat cancer
|
KR20190015407A
(en)
|
2016-06-03 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
Anti-PD-1 antibody for use in the treatment of recurrent small cell lung cancer
|
WO2017218707A2
(en)
*
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
US10711312B2
(en)
|
2016-07-12 |
2020-07-14 |
The Regents Of The University Of California |
Methods for immunotherapy-based treatment and assessment of cancer
|
JP7373991B2
(en)
|
2016-07-15 |
2023-11-06 |
ビラクタ セラピューティクス,インク. |
Histone deacetylase inhibitors for use in immunotherapy
|
CN110099687A
(en)
|
2016-08-18 |
2019-08-06 |
Uab研究基金会 |
Composition and method for immunotherapy for cancer
|
US10793632B2
(en)
*
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018071824A1
(en)
|
2016-10-13 |
2018-04-19 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
|
KR20240019398A
(en)
|
2016-10-28 |
2024-02-14 |
브리스톨-마이어스 스큅 컴퍼니 |
Methods of treating urothelial carcinoma using an anti-pd-1 antibody
|
US11644467B2
(en)
|
2016-12-01 |
2023-05-09 |
Yale University |
Prediction of response to immune-modulatory therapies
|
EA201991383A1
(en)
|
2016-12-07 |
2019-12-30 |
Эйдженус Инк. |
ANTIBODIES AGAINST CTLA-4 AND WAYS OF THEIR APPLICATION
|
CN110300599A
(en)
|
2016-12-07 |
2019-10-01 |
艾吉纳斯公司 |
Antibody and its application method
|
JP7165995B2
(en)
|
2017-02-21 |
2022-11-07 |
アールイーエムディー バイオセラピューティクス,インコーポレイテッド |
Cancer treatment using antibodies that bind to cytotoxic T lymphocyte antigen-4 (CTLA-4)
|
CN116440257A
(en)
|
2017-02-28 |
2023-07-18 |
百时美施贵宝公司 |
Use of anti-CTLA-4 antibodies with enhanced ADCC to enhance immune response to vaccine
|
US20220411506A1
(en)
|
2017-03-15 |
2022-12-29 |
Suzhou Galaxy Biopharma Co., Ltd. |
Ctla4 antibody, pharmaceutical composition and use thereof
|
WO2018178989A1
(en)
|
2017-03-30 |
2018-10-04 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Methods for treating melanoma
|
CN110505882A
(en)
|
2017-03-31 |
2019-11-26 |
默沙东公司 |
With the composition and method of the treatment of cancer with combinations of the antagonist and anti-CTLA 4 antibody of PD-1
|
EP3619236A1
(en)
|
2017-05-02 |
2020-03-11 |
Alligator Bioscience AB |
Bispecific antibody against ox40 and ctla-4
|
CA3060695A1
(en)
|
2017-05-02 |
2018-11-08 |
Merck Sharp & Dohme Corp. |
Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
|
EA201992755A1
(en)
|
2017-05-19 |
2020-04-22 |
Уси Байолоджикс (Шанхай) Ко. Лтд. |
NEW MONOCLONAL ANTIBODIES FOR PROTEIN 4 ASSOCIATED WITH CYTOTOXIC T-Lymphocytes, (CTLA-4)
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
EP3641752A4
(en)
|
2017-06-22 |
2021-03-17 |
Moonshot Pharma LLC |
Methods for treating cancer with compositions comprising amlexanox and immune modulators
|
TWI799432B
(en)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
Anti-ctla-4 antibodies and uses thereof
|
CN109420167B
(en)
|
2017-08-28 |
2022-02-11 |
四川九章生物科技有限公司 |
Combined medicine for treating tumor
|
JP7145895B2
(en)
|
2017-09-01 |
2022-10-03 |
四川科倫博泰生物医薬股▲フン▼有限公司 |
recombinant bispecific antibody
|
MX2020003132A
(en)
|
2017-09-21 |
2020-07-28 |
Eucure Beijing Biopharma Co Ltd |
Anti-ctla4 antibodies and uses thereof.
|
WO2019070834A1
(en)
|
2017-10-06 |
2019-04-11 |
David Weiner |
Dna monoclonal antibodies targeting ctla-4 for the treatment and prevention of cancer
|
US20210179714A1
(en)
|
2017-11-07 |
2021-06-17 |
Memorial Sloan Kettering Cancer Center |
Inhibition of CTLA-4 and/or PD-1 For Regulation of T Cells
|
WO2019113072A1
(en)
|
2017-12-05 |
2019-06-13 |
Intendet Services, Inc. |
Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
|